TriSalus Life Sciences, Inc. TLSI R2KPHARMA
Company Overview
TriSalus Life Sciences, Inc. engages in the research, development, and commercialization of drug delivery technology platform and immuno-oncology therapeutics to improve outcomes for patients with difficult-to-treat liver and pancreatic cancers in the United States. It offers Pressure-Enabled Drug Delivery (PEDD) infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial for treating locally advanced pancreatic cancer. The company is also developing nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma, intrahepatic cholangiocarcinoma, hepatocellular carcinoma, and pancreatic cancer. It serves interventional radiologists, IR technicians, medical oncologists, nursing support, and value analysis committee staff. The company was founded in 2009 and is headquartered in Westminster, Colorado.
Why Investors Should Care
Generates a return on equity of 115.9%, reflecting efficient use of shareholder capital.
Revenue has grown at a 53.8% CAGR over the past five years.
Recent Developments
- Dec 2025 Revenue of $45.15M (+53.4% YoY); net profit $-39.23M.
- Trailing 12 Months Year-on-year growth — revenue -2.9%.
- 5-Year Trend Long-term compounding — revenue CAGR 53.8%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 53.85% |
| 1 Year: | -2.90% |
Stock Price Performance
| 1 Year: | +26.58% |
| 6 Months: | +11.98% |
| 3 Months: | +57.73% |
| 1 Month: | +2.67% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)50.34 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Strong return on equity of 115.9%.
- Compounding revenue at 53.8% over 5 years.
CONS
- Trading 33.3% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | TLSI TriSalus Life Sciences, Inc. R2KPHARMA | 5.00 | -3.52 | $307.87M | 0.00% | -113.07% | 115.85% | 53.85% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,149.36 | 38.57 | $1.02T | 0.58% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 275.23 | 31.97 | $663.28B | 2.09% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 256.46 | 72.45 | $453.19B | 2.84% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 150.33 | 120.26 | $371.29B | 2.65% | - | 34.70% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 397.14 | 25.54 | $356.47B | 2.33% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 159.99 | 24.20 | $304.10B | 3.03% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 162.70 | 24.36 | $252.33B | 1.98% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 437.23 | 27.14 | $235.98B | 2.49% | 13.95% | 91.47% | 5.51% | 5.55% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | 3.92M | 2.98M | 4.61M | 5.19M | 6.46M | 7.36M | 7.35M | 9.17M | 11.21M | 11.57M | 8.90M | 11.41M |
| Gross Profit | - | - | - | - | - | 3.22M | 2.32M | 3.84M | 4.60M | 5.49M | 6.45M | 6.34M | 7.67M | 9.41M | 9.66M | 7.67M | 9.90M |
| Operating Income | -307.99K | -783.92K | -807.26K | -669.81K | -288.27K | -8.11M | -10.12M | -11.43M | -18.62M | -11.67M | -8.17M | -8.74M | -7.33M | -7.33M | -9.01M | -8.41M | -9.81M |
| Net Income | -372.03K | 378.87K | 1.86M | -7.87M | -8.68M | -8.09M | -8.31M | -13.98M | -1.43M | -13.21M | -4.33M | -2.40M | -10.38M | -8.29M | -10.81M | 1.54M | -9.19M |
| Diluted EPS | - | - | - | - | - | -25.95 | -0.57 | -35.84 | -0.14 | -0.60 | -0.21 | -0.12 | -0.39 | -0.27 | -0.96 | 0.03 | -0.16 |
| R&D Expense | - | - | - | - | - | 4.81M | 5.64M | 6.89M | 9.51M | 5.84M | 4.67M | 4.22M | 3.02M | 3.92M | 5.18M | 3.22M | 3.14M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 12.40M | 18.51M | 29.43M | 45.15M |
| Gross Profit | - | 10.14M | 15.91M | 25.33M | 38.19M |
| Operating Income | -3.04M | -36.44M | -54.48M | -36.16M | -26.95M |
| Net Income | 4.77M | -47.19M | -59.36M | -30.05M | -39.23M |
| Diluted EPS | - | -161.55 | -6.77 | -1.31 | -1.84 |
| R&D Expense | - | 21.36M | 29.84M | 17.69M | 14.96M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Sep 2020 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Total Assets | - | 252.01M | - | 22.00M | 24.60M | 23.97M | 35.33M |
| Current Assets | - | - | - | 17.21M | 20.86M | 20.67M | 32.24M |
| Cash & Equivalents | - | 1.33M | - | 9.41M | 11.78M | 8.53M | 20.44M |
| Inventory | - | - | - | 1.47M | 2.54M | 4.05M | 3.08M |
| Receivables | - | - | - | 1.56M | 3.55M | 5.09M | 6.56M |
| Total Liabilities | - | 23.50M | - | 198.32M | 51.66M | 49.87M | 69.19M |
| Current Liabilities | - | - | - | 32.36M | 14.69M | 10.23M | 11.50M |
| Long Term Debt | - | - | - | - | - | 22.08M | 33.05M |
| Total Debt | - | - | - | 1.96M | 1.59M | 23.63M | 34.44M |
| Total Equity | 0 | -21.48M | - | -176.33M | -27.07M | -25.89M | -33.86M |
| Shares Outstanding | - | - | - | 26.32M | 26.41M | 31.28M | 50.00M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | -1.74M | -32.31M | -50.58M | -40.84M | -18.01M |
| Investing Cash Flow | 60.00K | -1.79M | -1.59M | -345.00K | -838.00K |
| Financing Cash Flow | 544.00K | 13.46M | 54.63M | 37.94M | 30.76M |
| Capital Expenditure | - | -655.00K | -588.00K | -345.00K | -918.00K |
| Free Cash Flow | - | -32.97M | -51.17M | -41.19M | -18.93M |
| Share Buybacks | - | 232.37M | - | - | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | 81.8% | 85.9% | 86.1% | 84.6% |
| Operating Margin % | - | -293.9% | -294.3% | -122.9% | -59.7% |
| Net Margin % | - | -380.6% | -320.7% | -102.1% | -86.9% |
| ROE % | - | 26.8% | 219.3% | 116.0% | 115.8% |
| ROCE % | - | 351.7% | -549.6% | -263.2% | -113.1% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | First Light Asset Management, LLC | 10.64% | 6.55M | $31.65M |
| 2 | Blackrock Inc. | 4.32% | 2.66M | $12.84M |
| 3 | Vanguard Capital Management LLC | 2.81% | 1.73M | $8.35M |
| 4 | Cerity Partners LLC | 2.60% | 1.60M | $7.75M |
| 5 | Geode Capital Management, LLC | 1.93% | 1.19M | $5.75M |
| 6 | Nantahala Capital Management, LLC | 1.62% | 1.00M | $4.83M |
| 7 | Gilder Gagnon Howe & Co LLC | 1.38% | 850.08K | $4.11M |
| 8 | State Street Corporation | 0.99% | 610.96K | $2.95M |
| 9 | White Pine Capital LLC | 0.89% | 547.58K | $2.64M |
| 10 | Thompson, Siegel & Walmsley LLC | 0.87% | 536.53K | $2.59M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for TLSI
TLSI Forecast — Price Target — Prediction for 2027 - TradingView
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE1velBlREtoRkNEZGtSODlJb0lzZ05hLUFDMEFONUJ2N0Y1UEU4NWdXcWtneF9UYzJMdkFXbzFzWEs2NDU0Z05jeUZXZHVrQlE5Z1QzXzk4N0ROVmxlMnZYLU9POXJnclUwb1NJTEoybnpWaFhHRjRXRDNR?oc=5" target="_blank">TLS…
TRISALUS LIFE SCIENCES ($TLSI) Releases Q1 2026 Earnings | TLSI Stock News - quiverquant.com
<a href="https://news.google.com/rss/articles/CBMikwFBVV95cUxOSVN6NjY2NHJSbUNQWEM4MGFwQ0wzdTNzVmE2TWpCZWJQTUptV3lIY2tOM3FDR3M4Ti1vN1J1bnVEMVlhenhmQ3IxZFZxTHFpRERSMkRKZEl4WFFsckJ1c0FnR0FuNTZMaWFkME9WWEFnWTZtQXJQdXRMcVBnUWVvMWZVTmNEQ2ZiNXRaZE…
Earnings To Watch: TriSalus Life Sciences Inc (TLSI) Q2 2026 -- GF Value Sees 20% Upside - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMipAFBVV95cUxPMTRTOHF6eU43YmZ1TGlHSkFNdWRyTzRoRlhZenhDcV9KY2RiSkt4bnp6YS1KYWdWZHI1Uk5yWVRDOHdDSlhBMW5iOFNfcEhvZmJqajE0Yk50M2pJc3YtNmFNR1hnNDEzS2xvRGJfV0Q3UktNTE43QlQxcmxQeWprUl9yQ0ZxQ0loSzRmdE…
Avoiding Lag: Real-Time Signals in (TLSI) Movement - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMixwFBVV95cUxNTEtHZnlsWWxZb2ZSYkgtZ3NCYUo1VU9KS0hIbjYyblZlVGc3ODE1YzRRVXl2SkJWSXFWWFczV1B3ZC1IWTFIbjNmV1VweUZZOUR2MzYxRzB6eVJnbEpfSldHUUtJRVk5Zl9rSVdhd3AyMzRYd1d2T1ZZcWFMS18tdTA2VUhpUFBBRUttZl…
TriSalus Life Sciences, Inc. (TLSI) Reports Q1 Loss, Lags Revenue Estimates - Eastern Progress
<a href="https://news.google.com/rss/articles/CBMi5wFBVV95cUxNMkFtWnFSMDlJdjlPdmFxc1dXMkFjcEVKVUF6SlJRRGhyTDhfSmhFeVNsaVdsMXdwdHUwTW5yUl9nZWdhMlVrUFNMeFR4M0l6MHJuNlFOb0Fudnl4WjRNa1U4M2JxVHhlS0wzZzNfdlcwRzF6NS1QUkZXaTJQZ2NWcXNiTHBvSUZQNGRVcl…
TriSalus cancer device linked to fewer complications, $7.7K savings - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiswFBVV95cUxOY2JuVkg5cHBzVlI0S2s0T2NDb19GODF3X2dld3ZHYTJ0Z1JIQVFuaEkwXzA4d2VpMFZGMkxvWUNQeHF6TXlQaUNpNHpyaDlrbW5CMGxTbnNfaFpxYklGT2NlWURqcUxhOTl6dDluemJmdFlGZ0V3THZyam9ieEQ5YUR0c2kwM2NvSGtJWU…
TLSI — Frequently Asked Questions
What is the current share price of TriSalus Life Sciences, Inc. (TLSI)?
As of 2026-09-07 16:24 PDT, TriSalus Life Sciences, Inc. (TLSI) trades at $5.00 on NasdaqGM. Its 52-week range is $2.52 to $7.50.
What is the market capitalisation of TLSI?
TriSalus Life Sciences, Inc. (TLSI) has a market capitalisation of $307.87M on NasdaqGM.
What is the P/E ratio of TLSI?
TLSI trades at a trailing price-to-earnings (P/E) ratio of -3.52. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 26.84.
What is the return on equity (ROE) of TLSI?
TLSI has a return on equity (ROE) of 115.85%. Its return on capital employed (ROCE) is -113.07%.
Is TLSI a good stock to buy?
This page provides a data-driven analysis of TriSalus Life Sciences, Inc. (TLSI), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.